Trial · NCT07420439
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 24
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 1st line part: disease Control Rate at 8 weeks | 8 weeks from date of inclusion | Assessed by investigators according to RECIST 1.1. |
| Primary | 2nd line part: Treatment related respiratory worsening leading to discontinuation of treatment during the first 6 months | 6 months from randomisation | |
| Secondary | Progression-free survival | About 6 months | |
| Secondary | Duration of response | About 6 months | |
| Secondary | Overall Survival | About 20 months | |
| Secondary | Best overall response | About 6 months | |
| Secondary | 1st line part: Disease control rate at 8 weeks | 8 weeks | Assessed by Independent Central Review |
| Secondary | 2nd line part: Disease control rate at 8 weeks | 8 weeks | Assessed by Investigators |
| Secondary | Progression-free survival according to ILDs pattern on CT scan | About 6 months | |
| Secondary | Duration of response according to ILDs pattern on CT scan | About 6 months | |
| Secondary | Overall Survival according to ILDs pattern on CT scan | About 20 months | |
| Secondary | Best overall response according to ILDs pattern on CT scan | About 6 months | |
| Secondary | Progression-free survival according to ILDs severity (FVC/DLCO) | About 6 months | |
| Secondary | Duration of response according to ILDs severity (FVC/DLCO) | About 6 months | |
| Secondary | Overall Survival according to ILDs severity (FVC/DLCO) | About 20 months | |
| Secondary | Best overall response according to ILDs severity (FVC/DLCO) | About 6 months | |
| Secondary | Respiratory evolution (number of exaxerbations of ILD) with or without anti-fibrosing treatment | About 6 months | |
| Secondary | Progression-free survival with or without anti-fibrosing treatment | About 6 months | |
| Secondary | Duration of response with or without anti-fibrosing treatment | About 6 months | |
| Secondary | Overall Survival with or without anti-fibrosing treatment | About 20 months |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07420439/registered